BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials

Reuters

Jan 13

BUZZ-<a href="https://laohu8.com/S/MBRX">Moleculin Biotech</a> rises as cancer drug shows no heart damage in trials

** Shares of drug developer Moleculin Biotech MBRX.O rise 2.2% to $4.14 premarket

** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials

** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX

** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread

** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs

** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX

** Co says it is working to secure funding and will monitor patients long-term for heart issues

** As of last close, stock down ~92% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603768709"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603768709\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603768709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603768709","market":"fut","top_or_hot":-1,"title":"BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> rises as cancer drug shows no heart damage in trials</title></head><body><p>** Shares of drug developer Moleculin Biotech <span>MBRX.O</span> rise 2.2% to $4.14 premarket </p><p>** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials</p><p>** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX</p><p>** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread</p><p>** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs</p><p>** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX</p><p>** Co says it is working to secure funding and will monitor patients long-term for heart issues</p><p>** As of last close, stock down ~92% over the past year</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/MBRX\">Moleculin Biotech</a> rises as cancer drug shows no heart damage in trials</title></head><body><p>** Shares of drug developer Moleculin Biotech <span>MBRX.O</span> rise 2.2% to $4.14 premarket </p><p>** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials</p><p>** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX</p><p>** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread</p><p>** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs</p><p>** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX</p><p>** Co says it is working to secure funding and will monitor patients long-term for heart issues</p><p>** As of last close, stock down ~92% over the past year</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBRX","symbol_name":"Moleculin Biotech, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4N3YE1BP:1","article_id":"2603768709","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603768709","pubTimestamp":1768313362,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials** Shares of drug developer Moleculin Biotech MBRX.O rise 2.2% to $4.14 premarket ** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX** Co says it is working to secure funding and will monitor patients long-term for heart issues** As of last close, stock down ~92% over the past year","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBRX":"Moleculin Biotech, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Moleculin Biotech股价上涨，抗癌药物在试验中未显示心脏损伤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBRX":0.9},"content_text":"BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials** Shares of drug developer Moleculin Biotech MBRX.O rise 2.2% to $4.14 premarket ** Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials** Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX** Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread** Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs** Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX** Co says it is working to secure funding and will monitor patients long-term for heart issues** As of last close, stock down ~92% over the past year(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}